Drg Stimulator denied as experimental or investigational by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for drg stimulator are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Denied a Dorsal Root Ganglion Stimulator as Experimental

BCBS plans frequently classify dorsal root ganglion (DRG) stimulation as "experimental, investigational, or unproven" for certain diagnoses or patient profiles, despite the device holding FDA premarket approval (PMA). This denial reflects BCBS's medical policy determination that the evidence base — in its assessment — does not yet meet its internal standards for "established clinical benefit" for your specific indication. However, the FDA's PMA approval and coverage by other major payers are facts that support your appeal.

## Why This Is Appealable

An "experimental" classification by a private insurer is a coverage policy decision, not a clinical or regulatory verdict. The FDA has granted PMA approval for DRG stimulation for specific indications. Professional society guidelines from organizations such as the applicable pain medicine and neuromodulation societies provide evidence-based recommendations. These facts do not automatically override BCBS's policy, but they are grounds for a substantive appeal — particularly at external review, where an independent clinician reviews the evidence without deference to BCBS's internal policy.

## Federal Appeal Framework

• Internal appeal: File within 180 days. BCBS must respond within 30 days (pre-service standard), 72 hours (expedited), or 60 days (post-service).
• External review (ACA §2719): This is especially important for experimental denials. An IRO reviews the clinical evidence independently. File within 4 months of the final internal denial. The IRO's decision is binding.
• ERISA §503: Self-funded plans must provide full-and-fair review; courts scrutinize whether BCBS applied its policy consistently and with adequate evidence.
• Expedited review: Available if delaying treatment poses a serious health risk.

## Documentation to Gather

1. FDA PMA approval documentation — a copy or reference to the FDA's PMA decision for the specific DRG stimulation system, confirming regulatory approval for the relevant indication. 2. Professional society guidelines — statements or guidelines from relevant pain medicine, neuromodulation, or specialty societies endorsing DRG stimulation for your condition. 3. Peer-reviewed literature — published clinical studies on DRG stimulation for your specific diagnosis, gathered by your physician. 4. Diagnosis and severity records — chart documentation of your condition, its duration, severity, and functional impact. 5. Prescriber medical-necessity letter — addressing the specific experimental/investigational criteria in BCBS's current policy and why the evidence supports coverage. 6. Prior treatment failure documentation — a complete history of conservative and interventional treatments already attempted.

## Criteria-Mapping Structure

| BCBS Experimental-Coverage Criterion | Your Documentation | |---|---| | FDA approval status | [PMA reference] | | Peer-reviewed evidence of clinical benefit | [Literature citations from physician] | | Professional society endorsement | [Guideline citation] | | Diagnosis meets covered indication | [Diagnosis records] | | Prior treatment exhaustion | [Treatment history] |